Regulatory Roundup: FDA Clears Infant Rotavirus Vaccine

News
Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

FDA Clears Infant Rotavirus Vaccine

FDA stated on May 14, 2010, that US healthcare practitioners can resume the use of Rotarix (Rotavirus Vaccine, Live, Oral) used to treat the disease in infants, effective immediately. This action supersedes the agency’s March 22 recommendation, which called for healthcare providers to halt its use. FDA has determined that the presence of porcine circovirus type 1 (PCV-1) in the vaccine poses no safety risk.

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content
Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept. | Image Credit: © Dilok - stock.adobe.com

Sun Pharma Agrees to Acquire Checkpoint Therapeutics

Patrick Lavery
March 12th 2025
Article

The transaction includes Unloxcyt (cosibelimab-ipdl), which was approved by FDA in December 2024 for treatment of adults with cutaneous squamous cell carcinoma (cSCC).

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

March 26th 2024
Podcast

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

New Almac Pharma Services Commercial Manufacturing Facility Opens in Northern Ireland

Patrick Lavery
March 11th 2025
Article

The company’s 100,000-sq.-ft. space is expected to enhance its capabilities for commercial oral dose treatment manufacturing in a variety of therapeutic areas.

Drug Solutions Podcast: The Biosimilars Landscape

Drug Solutions Podcast: The Biosimilars Landscape

Feliza Mirasol
January 31st 2024
Podcast

In this episode of the Drug Solutions Podcast, industry experts give an overview of the biosimilars market and discuss factors affecting not only their manufacture, but their upstake in the market as well.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

Noramco Group Establishes Sterile Injectable Manufacturing Capabilities with $25 Million Investment

Patrick Lavery
March 10th 2025
Article

The investment is intended for the Halo Pharma facility in Whippany, NJ, and aims to help relieve capacity shortages in the injectable supply chain in the United States.

Magnified View of Lipid Nanoparticles | Image Credit: ©Aniwat - stock.adobe.com

Organic Nanoparticle-Based Drug-Delivery Systems as Alternatives to Lipid Nanoparticles

Cynthia A. Challener
March 9th 2025
Article

Exosomes, polymeric nanoparticles, and DNA nanostructures offer many potential advantages.